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Portal dosimetrya b s t r a c t
Background and purpose: Delivering selected parts of volumetric modulated arc therapy (VMAT) plans
using step-and-shoot intensity modulated radiotherapy (IMRT) beams has the potential to increase plan
quality by allowing specific aperture positioning. This study investigates the quality of treatment plans
and the accuracy of in vivo portal dosimetry in such a hybrid approach for the case of prostate radiotherapy.
Material and methods: Conformal and limited-modulation VMAT plans were produced, together with five
hybrid IMRT/VMAT plans, in which 0%, 25%, 50%, 75% or 100% of the segments were sequenced for IMRT,
while the remainder were sequenced for VMAT. Integrated portal images were predicted for the plans.
The plans were then delivered as a single hybrid beam using an Elekta Synergy accelerator with Agility
head to a water-equivalent phantom and treatment time, isocentric dose and portal images were mea-
sured.
Results: Increasing the IMRT percentage improves dose uniformity to the planning target volume (p < 0.01
for 50% IMRT or more), substantially reduces the volume of rectum irradiated to 65 Gy (p = 0.02 for 25%
IMRT) and increases the monitor units (p < 0.001). Delivery time also increases substantially. All plans
show accurate delivery of dose and reliable prediction of portal images.
Conclusions: Hybrid IMRT/VMAT can be efficiently planned and delivered as a single beam sequence.
Beyond 25% IMRT, the delivery time becomes unacceptably long, with increased risk of intrafraction
motion, but 25% IMRT is an attractive compromise. Integrated portal images can be used to perform
in vivo dosimetry for this technique.
 2016 The Royal Marsden NHS Foundation Trust. Published by Elsevier Ireland Ltd. Radiotherapy and
Oncology 120 (2016) 320–326. This is an open access article under the CC BY-NC-ND license (http://crea-
tivecommons.org/licenses/by-nc-nd/4.0/).It has been recognised very early in the development of volu-
metric modulated arc therapy (VMAT) that there might be a role
for a mixture of intensity-modulated radiotherapy (IMRT) and
VMAT beams in a hybrid approach [1]. This has been investigated
by Robar and Thomas [2], who find that target dose homogeneity is
improved with hybrid therapy compared to either a dynamic con-
formal arc or five-field IMRT separately, and that in prostate radio-
therapy, rectal dose is equivalent with hybrid therapy compared to
IMRT, but lower than with a dynamic conformal arc. In their solu-
tion, a 340 arc is used, with an additional equispaced five-field
IMRT beam arrangement superimposed. The same type of
approach, using IMRT beams in conjunction with a conformal arc,
is shown by Martin et al. [3] to be promising for treatment ofoesophagus, while Chan et al. [4] find that two partial RapidArc
beams, in conjunction with two IMRT beams accounting for around
50% of the total dose, are beneficial compared to conformal beams
and RapidArc for treatment of non-small cell lung cancer.
Probably the most sophisticated study is that of Matuszak et al.
[5], who begin with a conformal arc and successively introduce
IMRT beams, thereby obtaining a significant improvement of the
plan quality in several clinical examples. Selection of beam orien-
tations at which to use IMRT beams is on the basis of a gradient
measure, which reflects edges in the intensity maps.
All these methods begin with a relatively simple conformal arc
and add intensity-modulated beams at specific gantry angles. The
effect of this is that plan quality tends to improve with increased
percentage of IMRT as the IMRT component adds additional
degrees of freedom. However, if the starting point is a fully modu-
lated VMAT arc, it is not so clear whether the hybrid approach is
beneficial. Comparing a VMAT plan with an IMRT plan consisting
of the same number of segments, the differences are firstly that
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the segments in the IMRT plan are delivered at specific locations
in the beam’s eye view which may be separate from one another,
with no radiation being delivered between these locations. This
latter feature of IMRT may provide a small benefit in plan quality
which might be exploited in hybrid IMRT and VMAT delivery.
The present study aims to quantify this potential benefit.
A further aim of this study is to evaluate the performance of
in vivo portal dosimetry for hybrid IMRT and VMAT delivery. In
vivo portal dosimetry may be of the forward projection type, in
which integrated images are predicted during treatment planning
and then compared with the images obtained during treatment
[6,7], or it may be of the back projection type, where measured
images are back-projected to planes or volumes within the patient
to provide a dose distribution which can be compared with the
planned dose [8,9]. The latter approach is undoubtedly the more
sophisticated, as it provides a three-dimensional dose distribution
in the patient using gantry-resolved images. However, the former
approach is also a valuable indicator that the correct dose has been
delivered to the patient. The forward projection method has
recently been implemented at this centre for VMAT delivery [10]
and it is further evaluated in this study to examine its performance
in the context of hybrid delivery. The back projection method is
beyond the scope of this study.Materials and methods
Patients
Five consecutive prostate patients were retrospectively studied.
For their treatment, all of the patients were supine, with a full
bladder and empty rectum. Treatment plans were based on CT
scans with 2.5 mm slice spacing. Two clinical target volumes
(CTVs) were delineated, the first, CTVp, consisting of the prostate
alone, and the second, CTVpsv, consisting of the prostate plus sem-
inal vesicles. Median CTVp volume was 49.6 cm3 (range 20.6 cm3–
107.8 cm3) and median CTVpsv volume was 55.9 cm3 (range
25.8 cm3–114.2 cm3). Three planning target volumes (PTVs) were
produced from these volumes: PTV74 consisted of CTVp plus
5 mm in all directions except posteriorly, where the margin was
0 mm and the rectum was excluded; PTV71 consisted of PTV74
plus a further 5 mm in all directions, and PTV60 consisted of
CTVpsv plus 10 mm in all directions. The PTVs were arranged so
that the outer, larger volumes excluded the smaller, inner volumes.
Rectum, bladder, femoral heads (not including the necks) and
penile bulb were also contoured. A mean dose of 74 Gy in 37 frac-
tions was prescribed to PTV74, while 71 Gy and 60 Gy concomi-
tantly in 37 fractions were prescribed to PTV71 and PTV60
respectively.Treatment plans
Treatment plans were created using the AutoBeam in-house
inverse planning system (v5.6) [11,12] using the objectives given
in Supplementary Table 1. All plans used the 6 MV flattened beam
of a Synergy accelerator (Elekta AB, Stockholm, Sweden) with Agi-
lity MLC [13], and consisted of a single coplanar anticlockwise gan-
try rotation from gantry angle 110 to gantry angle 250, in accord
with previously determined class solutions for prostate radiother-
apy [14,15], but also as a practical means of avoiding couch bars
where present. Collimator was fixed at 2 throughout, so as to
spread out any interleaf leakage.
All plans consisted of 111 segments, nominally corresponding to
a 2 spacing (although this was adjusted in the case of the hybrid
plans; see below). The inverse planning process consisted of the
nowclassical three-stagemethod: fluence optimisation, sequencingand further optimisation of the deliverable treatment plan [11,12],
with hybridisation taking place as part of the sequencing step. Dur-
ing fluence optimisation, the gantry angles were grouped into seg-
ment groups of 20 width separated 22 apart and a fluence map
was produced using the iterative least squaresmethod at the central
gantry angle of each group. Each group was then sequenced into
deliverable segments using a double close-inmethodwhich succes-
sively closed theMLC in on one peak of the fluencemap, opened out
again, and then repeated the process on a further peak of the fluence
map. During sequencing, a chosen percentage of the control point
groups were selected for IMRT delivery, while the remainder
defaulted to VMAT delivery. Selection was on the basis of the com-
plexity of each fluence map, with the most complex groups being











where fi was the intensity at each pixel in the fluence map, fmeanwas
the mean fluence of the map, and f95 was the 95th percentile of the
fluence map, representing the maximum fluence with any outlying
high-intensity pixels removed.
The segments were then further optimised in terms of MLC leaf
positions and segment weights, again using iterative least squares
using previously described methods [12]. However, during this
process, IMRT segments were required to satisfy IMRT constraints
while the remaining VMAT segments were required to meet
dynamic delivery constraints. The IMRT constraints were a mini-
mum of 3 monitor units per segment, while the VMAT delivery
constraints were that the gantry should not reduce speed below
3/s, the collimator should not move faster than 80 mm/s, the
MLC leaves should not move more than 30 mm/s, the dose rate
should not reduce below 45 MU/min and also should not change
between segments by a factor of more than 4. All segments, regard-
less of whether delivered by IMRT or VMAT, were required to have
a minimum dimension of 15 mm, so as to allow accurate dose cal-
culation. During this process, dose was calculated using a fast con-
volution method incorporating tissue inhomogeneities [16].
Based on these concepts, seven plans were constructed for each
patient: the first of these, CO, was a conformal VMAT plan with 111
control points, but with all apertures conforming to the envelope of
the PTVs, plus a penumbra margin of 5 mm laterally and 6 mm in
the superior-inferior direction. Optimisation of this plan was lim-
ited to the segment weights. The second plan, LM, was a VMAT
plan with limited modulation: two out of three control point
groups were conformal, but every third control point group was
sequenced according to the sequencing method described above
[12] and then its MLC leaf positions and segment weights opti-
mised for VMAT. The remaining five plans, designated HY0 to
HY100, were hybrid plans with 0%, 25%, 50%, 75% and 100% IMRT
segments, with HY0 (0% IMRT) corresponding to normal, fully-
modulated VMAT delivery and HY100 (100% IMRT) corresponding
to a 10-beam IMRT plan with beams located every 22 (Fig. 1).
For all plans, the quality was assessed using the root-mean-
square dose variation from the prescribed dose in the PTVs, irradi-
ated volumes of rectum, bladder and femoral heads, and mean
dose to the penile bulb. The dose statistics were evaluated against
the dose constraints for the CHHiP trial [17–19], which were prin-
cipally that 99% of each PTV should receive >95% dose, rectum
V50Gy < 60%, rectum V65Gy < 30%, bladder V50Gy < 50%, bladder
V60Gy < 25%, femoral heads V50Gy < 50%. The dose statistics shown
in Supplementary Table 1 were also weighted according to
importance factor and negated in the case of objectives requiring
maximisation, and the sum of these weighted statistics was used
as a quality index, a lower value indicating better plan quality.
Fig. 1. Schematic diagram showing the concept of hybrid IMRT and VMAT optimisation and delivery. (a) The arc is divided into segment groups and fluence is optimised for
each group. (b) The segment groups are further optimised for either VMAT delivery (blue) or IMRT delivery (red). VMAT segments are distributed over the gantry range of
each segment group, while IMRT segments are all positioned at the central gantry angle of each segment group. The whole sequence is delivered as a single beam.
322 Hybrid IMRT and VMATThe total monitor units were recorded for each treatment plan.
Data were demonstrated by quantile–quantile plots to be normally
distributed and compared to the HY0 (normal VMAT) case using
two-tailed paired Student t-tests.Delivery and verification
In vivo portal imaging was simulated in a phantom scenario by
means of forward image prediction [10]. Following inverse
planning, each plan was recalculated with the isocentre locatedcentrally in a homogeneous water phantom of width 300 mm,
length 300 mm and height 200 mm. The mean dose at the centre
of the phantom in a volume representing a 0.6 cm3 Farmer
ionisation chamber (Saint Gobain Crystals and Detectors, Reading,
UK) was calculated. This volume was contained within a region
of PTV74 receiving a homogeneous dose. The planned doses
due to all segments of the hybrid plans were then forward
projected from the isocentre plane to the plane of the portal imager
and summed to give a single total predicted image for the
treatment.
Fig. 2. Mean dose–volume histograms for the seven different types of treatment plan. The insets to the histograms for PTV74, PTV71 and PTV60 show the transaxial, sagittal
and coronal dose distributions, respectively, for HY25.
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324 Hybrid IMRT and VMATThe hybrid treatment plans were then delivered to a water
equivalent phantom (Solid Water, Radiation Measurements, Inc.,
Madison, WI), using a Synergy accelerator. The total time for deliv-
ery of each plan was recorded and the dose at the centre of the
phantom was also recorded. The integrated portal image for each
plan was also measured using an iViewGT portal imager (Elekta
AB). The imaging panel was observed to reduce in output by 4%
when recording a 100  100 mm field delivered by 100 segments
of 3 MU each, compared to a single delivery of 300 MU, with the
accelerator output measured by an ionisation chamber as a refer-
ence [20,21]. The measured images were therefore increased by
1% for every 25% of IMRT to account for the low monitor units
per segment encountered in the IMRT components of the arcs.
All images were also increased by 3% to account for couch absorp-
tion, which was not included in the prediction model. The mea-
sured portal images were compared with the predicted images
using OmniPro I’mRT (IBA, Schwarzenbrück, Germany), using a
global gamma index for 3% and 3 mm and a dose threshold of
10%. Both the mean gamma index and percentage of measure-
ments with gamma index less than unity were recorded.Results
Mean dose–volume histograms for the seven types of treatment
plan are shown in Fig. 2 and the corresponding statistics are given
in Table 1. The conformal VMAT plan CO is not able to provide the
required doses to the three PTVs due to its conformal nature, and
the rectal and bladder doses are also very high, but this plan is
included for purposes of comparison as the baseline against which
the other techniques can be measured.
The limited modulation VMAT plan LM provides good coverage
of the PTVs but again irradiates a slightly large volume of rectum
and bladder, the rectal dose constraints used in the CHHiP trial
[17–19] being met but the bladder V60Gy being excessively high.
The hybrid IMRT and VMAT plans all provide good differentia-
tion of the PTV dose levels and adequate sparing of the rectum
and bladder. However, raising the IMRT component improves
PTV dose uniformity (p < 0.01 for 50% or more), reduces the volume
of rectum irradiated to 50 Gy (p < 0.05 except for 75% IMRT),
reduces the volume of rectum irradiated to 65 Gy (p < 0.05 for
25% IMRT and 50% IMRT) and increases the monitor units
(p < 0.001).
The distribution of IMRT segment groups is predominantly
anterior (Supplementary Fig. 1), indicating that the IMRT groupTable 1
Mean (±1 SD) statistics for the seven types of treatment plan.
CO LM Percentag
HY0
PTV74 RMS* (%) 4.6 ± 0.7 1.4 ± 0.1 2.1 ± 0.3
PTV71 minimum dose (Gy) 64.0 ± 3.2 63.6 ± 1.6 64.4 ± 2.2
PTV60 minimum dose (Gy) 60.2 ± 3.2 56.8 ± 1.6 55.6 ± 1.6
Rectum V30Gy (%) 81.1 ± 9.0 77.6 ± 9.1 76.9 ± 9.5
Rectum V50Gy (%) 55.9 ± 9.8 51.9 ± 9.6 43.8 ± 9.3
Rectum V65Gy (%) 21.2 ± 7.6 17.2 ± 5.9 15.2 ± 5.1
Bladder V50Gy (%) 39.5 ± 11.9 33.7 ± 10.8 31.5 ± 9.4
Bladder V60Gy (%) 32.0 ± 9.5 26.1 ± 8.8 23.6 ± 7.8
Femoral heads V50Gy (%) 0.0 ± 0.0 0.3 ± 0.7 0.0 ± 0.0
Penile bulb mean dose (Gy) 57.4 ± 12.7 57.4 ± 12.6 55.6 ± 12
Quality index 8.6 ± 0.7 8.0 ± 0.8 7.6 ± 0.7
Total monitor units 314 ± 11 347 ± 9 341 ± 10
Delivery time (s) 44 ± 2 56 ± 2 75 ± 4
Measured dose vs plan (%) 0.4 ± 0.6 0.3 ± 1.3 0.9 ± 1.3
Mean gamma 0.35 ± 0.06 0.34 ± 0.07 0.33 ± 0.0
Gamma < 1 (%) 99.1 ± 1.7 98.8 ± 2.2 98.7 ± 1.3
* RMS: root mean square dose variation.selection method is choosing gantry angles at which the fluence
distribution is higher laterally and lower in the central area, where
the rectum passes through the beam’s eye view. Use of IMRT in
such a situation means that the beam can be switched off while
the aperture passes from one side of the rectum to the other, which
improves the rectal sparing. However, this improvement in plan
quality is obtained at the expense of an increase in treatment time,
as the delivery time increases considerably with increased percent-
age of IMRT (Table 1).
All types of plan can be delivered reliably, with measured
isocentric doses within 3% of the planned dose (Table 1). Agree-
ment between measured and predicted portal images is closest
for CO and LM due to the simple nature of the segments, but the
agreement of the hybrid plans is also good. Sample images are
shown in Fig. 3 and the full results are given in Table 1.Discussion
These results confirm that adding modulation to selected parts
of a conformal VMAT arc can improve the plan quality. The confor-
mal VMAT arc (CO) is very simple and in this study is unable to dif-
ferentiate between the dose levels required for the different PTVs.
However, introducing modulated sections of arc improves the plan
quality considerably (LM), without impacting very much on the
overall treatment time. However, a fully modulated VMAT arc
(HY0) provides considerably superior plan quality to either of these
options. The more important question is therefore: how much
improvement can be achieved by use of IMRT for some of the sec-
tions of VMAT arc? This study shows that plan quality definitely
improves by the use of IMRT for some of the sections, with maxi-
mum benefit achieved with 100% IMRT. However, this increases
the treatment time, which in turn increases the likelihood of
intrafraction motion [22–25], so it is likely that there is a trade-
off between improved plan quality due to increased IMRT and
degrading dosimetry due to long treatment time. Several authors
have evaluated the relationship between intrafraction motion
and treatment dosimetry [26,27], but the impact of treatment time
on this relationship is not very clear, so a pragmatic compromise is
recommended, such as 25% IMRT. Time available for treatment of
the patient is also an important factor which varies from centre
to centre.
These results are similar to those of Robar and Thomas [2], who
find that target dose homogeneity is improved with hybrid therapy
compared to either a dynamic conformal arc or five-field IMRTe IMRT in hybrid plan
HY25 HY50 HY75 HY100
2.0 ± 0.2 1.8 ± 0.3 1.4 ± 0.2 1.2 ± 0.1
64.9 ± 2.1 65.0 ± 2.1 65.2 ± 1.9 65.1 ± 1.8
55.8 ± 1.8 55.9 ± 1.9 56.1 ± 1.8 56.5 ± 2.0
76.2 ± 10.2 78.3 ± 9.8 77.3 ± 9.7 74.7 ± 10.0
41.8 ± 8.2 41.3 ± 8.2 40.5 ± 7.9 39.5 ± 8.0
13.6 ± 4.3 13.4 ± 4.0 13.3 ± 4.0 13.2 ± 3.9
32.6 ± 9.6 33.8 ± 10.5 32.9 ± 10.2 32.0 ± 10.3
23.8 ± 7.7 24.0 ± 7.7 23.9 ± 7.5 23.8 ± 7.5
0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
.7 56.8 ± 12.7 57.2 ± 13.1 57.3 ± 13.3 57.3 ± 13.4
7.4 ± 0.7 7.4 ± 0.6 7.3 ± 0.6 7.1 ± 0.6
376 ± 11 388 ± 14 400 ± 12 406 ± 11
202 ± 10 277 ± 17 379 ± 26 439 ± 36
1.1 ± 1.3 1.2 ± 1.6 0.4 ± 0.9 0.0 ± 1.0
8 0.39 ± 0.09 0.39 ± 0.09 0.44 ± 0.18 0.48 ± 0.14
95.6 ± 4.8 97.1 ± 3.8 93.1 ± 10.5 93.3 ± 9.3
Fig. 3. Typical portal imaging results for HY25. (a) predicted image, (b) measured
image, and (c) gamma distribution for 3% and 3 mm.
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compared to IMRT, but lower than with a dynamic conformal
arc. The results are also broadly in agreement with those of Matus-
zak et al. [5], who begin with a conformal arc and successively
introduce IMRT beams, thereby obtaining a significant improve-
ment of the plan quality in their prostate phantom case.
The reduction in irradiated volume of rectum at the 65 Gy level
seen in the hybrid plans is likely to result in a small reduction in
the probability of grade 2 rectal toxicity [28–30]. This is achieved
without significant detriment to any of the other dose statistics.
Meanwhile, the improvement in PTV homogeneity seen with the
hybrid plans contributes to accurate dose delivery, particularly in
the presence of any intrafraction motion. It is likely to be theimproved PTV coverage which gives rise to the small and statisti-
cally insignificant increase in mean dose to the penile bulb.
In vivo portal dosimetry also functions reliably for hybrid IMRT
and VMAT treatment plans. The results show that the forward pre-
diction method is able to conveniently predict the expected inte-
grated images to within 3% and 3 mm, which is acceptable for
clinical use and considerably better than the 5% and 5 mm agree-
ment recommended by ICRU 83 for pre-treatment verification
[31]. This is important, because the introduction of a new tech-
nique in a modern setting requires corresponding quality measures
to be similarly included [32]. For prostate, in vivo portal dosimetry
is in widespread clinical use for treatment verification [9], increas-
ingly as the sole dosimetric measure [33], so demonstration of
accurate performance of in vivo portal dosimetry for hybrid IMRT
and VMAT is essential. Further work is needed to implement back
projection in vivo portal dosimetry for hybrid delivery and to
investigate the differences between the forward and back projec-
tion methods.
Conclusion
Hybrid IMRT/VMAT can be efficiently planned and delivered as
a single beam sequence, giving improved target dose homogeneity
and rectal sparing. Beyond 25% IMRT, the delivery time becomes
unacceptably long, with increased possibility of intrafraction
motion, but 25% IMRT is an attractive compromise. Integrated por-
tal images can be used to perform accurate in vivo dosimetry for
this technique.
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